PATENT CLAIM ANALYSIS

Application Number: 15758098
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "312000"]

Abstract:
The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for the treatment of Leukodystrophy, in particular, peroxisomal disorders including Zellweger syndrome.

Claim (Index 34):
The method of  claim 1  wherein the compound is orally administered to the patient.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 90.0
- Lexical Diversity: 1.54286
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13417030', '14182994', '13417028', '11482926', '16301711']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7095598419099348
- 35 USC 102 Novelty (BERT): 0.5188638592646557
- Combined Prediction Score: 0.6904902436454069
- Mean Citation Score: 176.222894
- Max Citation Score: 180.24554
- Similarity Product: 95.11616360376358

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test